Zentalis Pharmaceuticals (ZNTL) Preferred Stock Liabilities (2019 - 2020)
Zentalis Pharmaceuticals (ZNTL) recorded quarterly Preferred Stock Liabilities of $155.9 million in Q1 2020, up 10.04% quarter-over-quarter from $141.7 million in Q4 2019.
Zentalis Pharmaceuticals (ZNTL) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Zentalis Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $155.9 million for Q1 2020.
- In Q1 2020, Preferred Stock Liabilities changed N/A year-over-year to $155.9 million; the TTM figure through Mar 2020 stood at $155.9 million (changed N/A YoY), while the FY2019 annual figure was $141.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $155.9 million for Q1 2020 at Zentalis Pharmaceuticals, up from $141.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $155.9 million in Q1 2020 to a low of $141.7 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Zentalis Pharmaceuticals | 264.90 Mn | 264.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 155.93 Mn |
| Dec 31, 2019 | 141.71 Mn |
| Sep 30, 2019 | 141.71 Mn |